Surface Oncology Inc (SURF) Stock
SURF is no longer traded. Surface Oncology was delisted from the Nasdaq in September 2023.
Prices on this page are historical; the last trade was September 7, 2023 at $1.07.
Surface Oncology stock price history
SURF final trading statistics
- Final close
- $1.07
- Final trading day
- Sep 7, 2023
- Market cap at delisting
- $65.08M
- Shares outstanding
- 60.82M
- Final 52-week range
- $0.56 – $1.43
- Avg. volume (final 3 mo.)
- 799,004
- All-time high (split-adj.)
- $17.83 · Jul 2018
- All-time low (split-adj.)
- $0.57 · Apr 2023
- Return since IPO
- -92.0%
- Beta
- 1.75
- Book value / share
- $0.81
- Price / book
- 1.32
Surface Oncology annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $30.00M | -$65.3M | -$1.07 |
| FY2021 | $2.69M | -$79.5M | -$1.77 |
| FY2020 | $126.16M | $59.3M | $1.47 |
| FY2019 | $15.36M | -$53.0M | -$1.97 |
| FY2018 | $59.42M | -$6.6M | $6.03 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.
Surface Oncology stock FAQ
What happened to Surface Oncology stock?
Surface Oncology stock was delisted from the Nasdaq. Its final close was $1.07 on September 7, 2023.
Is SURF stock still trading?
No. SURF was delisted from the Nasdaq in September 2023 and no longer trades on a U.S. exchange.
What was the last price of SURF stock?
SURF closed at $1.07 on its final trading day, September 7, 2023, for a market value of about $65.08M.
What were Surface Oncology's revenue and earnings in its last full fiscal year?
Surface Oncology reported revenue of $30.00M and net income of -$65.3M in fiscal 2022, its last full year as a public company.
When did Surface Oncology go public?
Surface Oncology Inc stock began trading on April 19, 2018.